Recombinant Protective Antigen Expression for Anthrax Vaccine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anthrax vaccines are poorly defined, leading to variability in toxin component concentrations, potential toxicity, and inconsistent efficacy due to the inclusion of PA, LF, and EF, which can form harmful toxin complexes, and lack of understanding in manufacturing processes.
Innovation Solution
Development of recombinant Bacillus anthracis Protective Antigen (rPA) using modified nucleic acid sequences to enhance expression levels and stability, combined with optimized production methods and downstream processing to produce a more consistent and purified vaccine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional anthrax vaccine manufacturing using B. anthracis cultures is used, then vaccine production is achieved, but the vaccine composition is poorly defined with variability in toxin component concentrations
Solution Approach 1:
The patent extracts and isolates only the protective antigen (PA) component from the complex B. anthracis culture mixture, removing the harmful LF and EF toxins. This is achieved through selective culture conditions and purification procedures that yield PA-rich preparations, eliminating the source of compositional variability and toxicity while maintaining vaccine efficacy.
Solution Approach 2:
The patent modifies the manufacturing parameters by using defined media compositions, controlled temperature conditions (37°C), and specific pH ranges (7.4-7.6) to optimize PA production. These parameter changes enable consistent, reproducible PA concentrations in the vaccine preparation, transforming the unpredictable traditional process into a precision manufacturing system.
2Reliability
If traditional anthrax vaccine containing PA, LF, and EF is used, then vaccine production is achieved, but harmful toxin complexes may form causing potential toxicity
Solution Approach 1:
The patent removes the harmful LF and EF toxin components from the vaccine formulation, extracting only the protective PA antigen. This extraction eliminates the ability of PA to form harmful toxin complexes with LF and EF, thereby removing the source of toxicity while preserving the protective immune response.
Solution Approach 2:
The patent converts the potentially harmful PA protein into a beneficial vaccine component by producing it in a controlled manner that prevents toxin complex formation. The PA is produced as a stable, non-toxic antigen that elicits protective immunity without the harmful effects of its native toxin complexes.
3Reliability
If traditional anthrax vaccine manufacturing is used, then vaccine production is achieved, but there is lack of understanding in manufacturing processes leading to inconsistent efficacy
Solution Approach 1:
The patent performs preliminary characterization and definition of the PA protein properties, including its molecular weight, structure, and immunogenicity, before incorporating it into the vaccine formulation. This preliminary understanding of the antigen's characteristics enables precise control over vaccine manufacturing and ensures consistent efficacy across production batches.
4Productivity
If recombinant PA production with modified nucleic acid sequences is used, then expression levels are enhanced, but production complexity increases
Solution Approach 1:
The patent uses recombinant DNA technology to copy the PA gene into a suitable expression vector system, allowing high-level production in a controlled host organism. This copying approach enables optimized expression levels through vector selection and gene engineering while maintaining a manageable production process through standardized recombinant protein techniques.
Data Source
AI summary
A polynucleotide sequence is provided comprising a nucleic acid sequence encoding recombinant Protective Antigen (rPA).Also provided are expression vectors and host cells comprising the polynucleotide sequence of the invention, and methods for producing rPA.